Amolyt Pharma
Signal active
Organization
Contact Information
Overview
Amolyt Pharma specializes in peptides for the treatment of rare endocrine and metabolic disorders. Its programs include AZP-3601, a parathyroid hormone analog, for the potential treatment of hypoparathyroidism, and AZP-3404, a peptide with a new and unique mechanism of action, that may restore fat and glucose metabolism.
About
Industries
Biotechnology, Health Care, Pharmaceutical, Medical, Wellness
Founded
2015
Employees
11-50
Headquarters locations
Europe
Social
N/A
Profile Resume
Amolyt Pharma headquartered in Europe, operates in the Biotechnology, Health Care, Pharmaceutical, Medical, Wellness sector. The company focuses on Biotechnology and has secured $56.0B in funding across 180 round(s). With a team of 11-50 employees, Amolyt Pharma is actively contributing to advancements in Biotechnology. Their latest funding round, Venture Round - Amolyt Pharma, raised $4.1M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
9
Investors
2
Lead Investors
0
Total Funding Amount
$311.3M
Details
4
Amolyt Pharma has raised a total of $311.3M in funding over 4 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2019 | Early Stage Venture | 74.2M | ||
| 2021 | Early Stage Venture | 80.0M | ||
| 2023 | Late Stage Venture | 138.6M | ||
| 2014 | Early Stage Venture | 6.5M |
Investors
Amolyt Pharma is funded by 83 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Bpifrance | - | FUNDING ROUND - Bpifrance | 6.5M |
| Octalfa | - | FUNDING ROUND - Octalfa | 4.1M |
| Amolyt Pharma | - | FUNDING ROUND - Amolyt Pharma | 4.1M |
| Sham | - | FUNDING ROUND - Sham | 4.1M |
Recent Activity
There is no recent news or activity for this profile.